Motugivatrep

Motugivatrep
Clinical data
Trade names	Avarept
Other names	SJP-0132; DA-55647; HY-145582; CS-0376446; D12841
Legal status
Legal status	Rx in Japan;
Identifiers
	IUPAC name (2E)-N-[(7R)-7-Hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-2-[7-(trifluoromethyl)-2,3-dihydrochromen-4-ylidene]acetamide;
CAS Number	920332-28-1;
PubChem CID	137350798;
ChemSpider	128921697;
UNII	7SHP2FH6HQ;
KEGG	D12841;
ChEMBL	ChEMBL5095073;
Chemical and physical data
Formula	C22H20F3NO3
Molar mass	403.401 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC2=C(C[C@@H]1O)C(=CC=C2)NC(=O)/C=C/3\CCOC4=C3C=CC(=C4)C(F)(F)F;
	InChI InChI=1S/C22H20F3NO3/c23-22(24,25)15-5-7-17-14(8-9-29-20(17)11-15)10-21(28)26-19-3-1-2-13-4-6-16(27)12-18(13)19/h1-3,5,7,10-11,16,27H,4,6,8-9,12H2,(H,26,28)/b14-10+/t16-/m1/s1; Key:MAWBBYZCTDJMDD-HFQYIWAZSA-N;

Motugivatrep (brand name Avarept) is an ophthalmic drug. In Japan, it is approved to treat dry eye disease.^[1]

Other namesSJP-0132; DA-55647; HY-145582; CS-0376446; D12841

Quick facts Clinical data, Trade names ...

Close

References